STUDII CLINICE



1. EXTEND (Eltrombopag Extended Dosing Study). An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial.

EXTEND (Eltrombopag Extended Dosing Study). Studiu deschis, de ajustare a dozei, de extensie, pentru a evalua siguranta si eficacitatea eltrombopag in tratamentul subiectilor cu purpura trombocitopenica idiopatica care au fost inrolati anterior intr-un studiu cu eltrombopag.

Investigator principal Dr. Razvan Stoia. Activ, nu recruteaza. Contact: razvan_stoia@yahoo.com

2. Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMJ).

Studiu al Vorinostat (MK-0683), un inhibitor HDAC sau Placebo, in combinatie cu Bortezomib la pacienti cu mielom multiplu.

Investigator principal Dr. Razvan Stoia. Activ, nu recruteaza. Contact: razvan_stoia@yahoo.com

3. Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma.

Studiu al combinatiei Rituximab, Ciclofosfamida, Doxorubicina, Velcade si Prednison sau Rituximab, Cyclophosphamide, Doxorubicin, Vincristin si Prednison la pacienti nou diagnosticati cu limfom al mantalei.

Investigator principal Dr. Razvan Stoia. Activ, recruteaza. Contact: razvan_stoia@yahoo.com

4. Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial).

Studiu al eficacitatii si sigurantei Lenalidomid versus Chlorambucil ca prima linie de tratament la pacienti varstnici cu leucemie limfatica cronica B (studiul ORIGIN).

Investigator principal Dr. Razvan Stoia. Activ, recruteaza. Contact: razvan_stoia@yahoo.com

5. A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL).

Studiu de evaluare a eficacitatii si sigurantei Lenaldomid ca tratament de intrtinere pentru pacienti cu leucemie limfatica cronica B dupa tratament de linia a doua (studiul CONTINUUM).

Investigator principal Dr. Razvan Stoia. Activ, recruteaza. Contact: razvan_stoia@yahoo.com

6. Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1).
Studiu de faza III al Lenalidomid si Dexametazon cu sau fara Elotuzumab pentru tratamentul pacientilor cu mielom multiplu, nou diagnosticati, netratati anterior (studiul ELOQUENT – 1)

Investigator principal Dr. Razvan Stoia. In pregatire, nu inroleaza inca (Dec 2011). Contact: razvan_stoia@yahoo.com

7. Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT – 2).

Studiu de faza III, deshis, randomizat al lenalidomid/Dexametazon cu sau fara Elotuzumab in mielomul multiplu in recadere sau refractar (studiul ELOQUENT – 2)

Investigator principal Dr. Razvan Stoia. In pregatire, nu inroleaza inca (Dec 2011). Contact: razvan_stoia@yahoo.com

8. A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma.

Studiu randomizat, controlat, dublu orb, de faza III pentru a compara eficacitatea, siguranta si farmacocinetica GP2013 plus CVP vs MabThera plus CVP, urmat de tratament de intretinere cu GP2013 sau Mabthera la pacienti cu limfom folicular avansat, netratati anterior.

Investigator principal Dr. Razvan Stoia. In pregatire, nu inroleaza inca (Dec 2011). Contact: razvan_stoia@yahoo.com

9. Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase (ENEST1st).

Nilotinib la pacienti adulti nou diagnosticati cu leucemie mieloida cronica cu cromozom Philadelphia si/sau BCR-ABL pozitivi (studiul ENEST1st).

Investigator principal Conf. Dr. Daniel Coriu. Activ, nu inroleaza. Contact: daniel_coriu@yahoo.com

10. A Prospective, Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP).

Studiu prospectiv, deschis, multicentric de faza IV pentru evaluarea schimbarilor morfologice din maduva osoasa la pacienti adulti care primesc romiplostim pentru tratarea trombocitopeniei asociata cu purpura trombocitopenica imuna (PTI)

Investigator principal Dr. Mariana Vasilica. Activ, nu inroleaza. Contact: m.vasilica@yahoo.com

11. A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Studiu de faza II pentru evaluarea adaugarii terapiei cu MabThera (Rituximab) la chimioterapia prescrisa in mod current la pacientii cu limfom al celulei de manta netratat.

Investigator principal Dr. Mariana Vasilica. Activ, inroleaza. Contact: m.vasilica@yahoo.com

12. CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

CLL11: Studiu al RO5072759 plus Chlorambucil la pacienti cu leucemie limfatica cronica netratati anterior.

Investigator principal Dr. Mariana Vasilica. Activ, inroleaza. Contact: m.vasilica@yahoo.com

13. A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin’s Lymphoma.

Studiu al MabThera (Rituximab) subcutanata vs MabThera (Rituximab) intravenos la pacienti cu limfom folicular.

Investigator principal Dr. Mariana Vasilica. Activ, inroleaza. Contact: m.vasilica@yahoo.com

14. Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Relapsed Mantle Cell Lymphoma

Compararea a 2 doze de Temsirolimus (Torisel) la pacienti cu limfom al mantalei in recadere.

Investigator principal Dr. Andreea Delia Moicean. Activ, inroleaza. Contact: deliadi@xnet.ro

15. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial).

Studiu de faza III a Brentuximab Vedotin (SGN-35) la pacienti Boala Hodgkin, cu risc inalt de boala reziduala dupa transplant de celule stem. (studiul AETHERA).

Investigator principal Dr. Anca Popp. Activ, inroleaza. Contact: b55ank@yahoo.com

16. Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia.

Ofatumumab in asociere cu Fludarabina-Ciclofosfamida vs Fludarabina-Ciclofosfamida la pacienti cu leucemie limfatica cronica in recadere.

Investigator principal Dr. Andreea Delia Moicean. Activ, inroleaza. Contact: deliadi@xnet.ro

17. Anagrelide Retard vs. Placebo: Efficacy and Safety in “At-risk” Patients With Essential Thrombocythaemia (ARETA).

Anagrelid retard vs Placebo: eficacitate si siguranta la pacientii cu trmbocitemie esentiala cu risc (studiul ARETA).

Investigator principal Dr. Emilia Niculescu Mizil. Activ, inroleaza. Contact: nmemilia@gmail.com

18. Study of Elacytarabine Versus Investigator’s Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA).

Studiu al Elacytarabina vs “optiune investigatorului” la pacienti cu leucemie acuta mieloida in stadiu avansat (studiul CLAVELA).

Investigator principal Dr. Andreea Delia Moicean. Activ, inroleaza. Contact: deliadi@xnet.ro

19. Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma.

Studiu de faza III care compara Carfilzomib, Lenalidomid si Dexamatazon (CRd) vs Lenalidomid si Dexametazon (Rd) la subiecti cu mielom multiplu in recadere.

Investigator principal Conf. Dr. Adriana Colita. Activ, inroleaza.

20. Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor ALL (BLAST)

Studiu de faza II al Blinatumomab (MT103) la pacienti cu leucemie acuta limfoida cu precursori B si boala minima reziduala (studiul BLAST).

Investigator principal Dr. Andreea Delia Moicean. Activ, inroleaza. Contact: deliadi@xnet.ro

21. Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

Studiul supravietuirii fara evenimente la pacienti cu sindroame mielodisplazice care primesc tratament chelator de fier (studiul TELESTO).

Investigator principal Dr. Andreea Delia Moicean. Activ, inroleaza. Contact: deliadi@xnet.ro